Study Looking at a Different Treatment for Chronic Myeloid Leukemia

What we are studying

The purpose of this study is to evaluate the molecular relapse-free rates 6 months after stopping therapy in patients who have very low level of leukemia cells in your blood. These levels indicate how well your disease is under control by the treatment.

Who we are studying

  • Men and Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 18+

Eligibility Criteria

  • Diagnosed with chronic myeloid leukemia
  • At least 1 year of imatinib treatment prior to study entry

What is involved

  • You will be asked to come to the Outpatient Comprehensive Cancer Center up to 12 times over 2 years during the Monitoring Phase
  • 4 times over 1 year or 8 times over 2 years during the Consolidation Phase
  • 19 times in the Treatment-Free Remission phase

Compensation

None

Contact Information

Study Coordinator
Jennifer MacLean
Email
jemaclea@wakehealth.edu
Phone
336-713-3539

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.